H
ospitalizations for acute decompensated heart failure (ADHF) account for the majority of >$30 billion spent on heart failure (HF) annually in the United States (1) . Moreover, the evaluation of these patients adds nearly 1 million emergency department (ED) evaluations annually, and exacerbates ED overcrowding (2) . Despite data suggesting that >50% of this population has a low risk of serious complications, >80% are admitted to the hospital (3). Low-risk patients with ADHF may be candidates for outpatient management and follow-up. However, to execute such a strategy, accurate risk stratification is essential. The report by Pang et al. (4) in this issue of JACC: Heart Failure addresses whether measurement of high-sensitivity cardiac troponin (hsTn) on ED arrival might identify low-risk patients with ADHF and potentially avoid hospitalizations. This approach shares some analogy to the "rule-out myocardial infarction" strategy in patients with chest pain. Given challenges in diagnosis, variability in prognosis, and pressures to reduce hospital admissions, an evidence-based strategy to drive triage and management decisions is appealing.
TROPONIN AND THE IDENTIFICATION OF LOW-RISK PATIENTS WITH ADHF
In prior studies of ADHF, higher concentrations of cardiac troponin measured with earlier-generation assays were strongly associated with poor outcomes.
Depending on the assay, the proportion of patients with an elevated cardiac troponin ranges from 6.2% (5) to w50% (6). In the RELAX-AHF-1 (RELAXin in Acute Heart Failure) trial of patients with ADHF randomized to serelaxin or placebo, the great majority of patients (>90%) had high-sensitivity cardiac troponin T (hsTnT) levels >99th percentile upper reference limit of 14 ng/l (0.014 mg/l), with an increasing gradient of risk of cardiovascular death and rehospitalization for HF with higher concentrations above that threshold (7) . The authors' present analysis focuses on 107 patients (9.9% of the cohort) with hsTnT <14 ng/l.
Compared with patients with elevated hsTnT, patients with hsTnT <14 ng/l were healthier, had less ischemic disease, and had better New York Heart As- It is also possible that a low hsTn is actually "ruling out" ADHF and that patients identified in this manner in RELAX-AHF either had chronic HF without acute decompensation or did not have HF at all. We speculate that it is unlikely for a patient to have ADHF without any myocardial injury detectable using hsTn.
Nevertheless, from the viewpoint of a triage algorithm keyed on low risk, the distinction among the mechanism of disease, diagnosis, and prognosis is not critical; very low-risk patients, regardless of diagnosis, may not require admission.
CLINICAL CONSIDERATIONS
Although patients with hsTnT <14 ng/l in RELAX-AHF were at very low mortality risk, the assertion that outcomes would be the same with discharge from the ED is not directly supported by the study. Such patients were, on average, hospitalized for 8 days, suggesting that they were perceived to need ongoing in-hospital management. Prospective studies randomizing potentially low-risk patients to outpatient versus inpatient management would be required to reach definitive conclusions regarding whether discharge from the ED will achieve equivalent outcomes.
ADDITIONAL AREAS FOR RESEARCH
The hsTn assays open new vistas for clinical research and care in HF (11) . There are 3 key aspects (12) 
